Armata posts promising phage trial results but faces acute liquidity crunch

Armata Pharmaceuticals, Inc. (NYSE: ARMP)

Quick read: Armata is a clinical‑stage phage therapeutics company showing positive clinical readouts (AP‑SA02 and AP‑PA02) while aggressively cutting operating spend. At the same time the company faces acute liquidity strain, heavy debt with expensive related‑party loans, and earnings volatility driven by fair‑value accounting of a convertible loan.

Key facts & statistics (as reported, $ in thousands unless noted)
- Cash and cash equivalents: $4,328 (June 30, 2025)
- Restricted cash: $5,390; Cash + restricted cash: $9,718 (six months ended June 30, 2025)
- Total assets: $80,790; Total liabilities: $150,293; Total stockholders' deficit: $(69,503) (June 30, 2025)
- Accumulated deficit: $(350,561) (June 30, 2025)
- Total current assets: $7,520 vs. Total current liabilities: $120,085 (June 30, 2025) - large short‑term mismatch
- Convertible Loan, current: $33,445 (fair‑value measured liability) (June 30, 2025)
- Term debt, current: $78,891 (June 30, 2025)
- Q2 2025 grant & award revenue: $2,169 (Q2) - $2,660 (six months 2025)
- Operating expenses (Q2 2025): R&D $6,394; G&A $2,619; Total operating expenses $9,013
- Operating loss (Q2 2025): $(6,844); Net loss (Q2 2025): $(16,295) (Net loss six months 2025: $(22,826))
- Interest expense (six months 2025): $7,410; Change in fair value of Convertible Loan (six months 2025): $(548)
- Shares outstanding (basic): 36,193,479 (as of June 30, 2025)
- MTEC award (DoD) increased to $26.2M and extended to March 31, 2026 (provides non‑dilutive funding for AP‑SA02)
- Subsequent event: August 11, 2025 Innoviva loan of $15.0M at 14.0% (secured; matures Jan 11, 2029)

What's happening inside the company
- Management has reduced R&D and G&A vs. prior year (R&D down ~24.6% Q2 YoY; total operating expenses down ~24.3% Q2) - a deliberate cost control move.
- Clinical progress is a material operational positive: AP‑SA02 reported statistically significant improvements in responder rates in the Phase 1b/2a diSArm study; AP‑PA02 showed encouraging Phase 1b/2a and Phase 2 signals. These results underpin management's push toward a pivotal program pending funding.
- Financing activity is concentrated with Innoviva (related‑party). The company has layered high‑rate term loans (14% stated rates) and amendments/extensions of the convertible facility - producing significant interest accruals and fair‑value volatility.
- Liquidity has become the core operational focus: cash is low and management discloses substantial doubt about going concern; they are pursuing additional financings, partnerships and grants.

Income statement - positives
- Grant & award revenue increased (six months 2025: $2,660 vs. $966 prior year) - non‑dilutive program support for AP‑SA02 (MTEC).
- Operating cost discipline: R&D and G&A declined materially YoY (six months R&D down $4.7M; G&A down $0.7M), improving cash burn if sustainable.
- Clinical outcomes add potential revenue upside long term: positive AP‑SA02 and AP‑PA02 trial results strengthen the commercialization case.

Income statement - negatives
- Net loss widened six months to $(22,826) and Q2 net loss $(16,295).
- Significant non‑operating volatility: change in fair value of the Convertible Loan swung from a large gain in 2024 to a loss in 2025 (Q2 2025: $(5,751)) - creates noisy, unpredictable earnings swings.
- Rising interest and financing costs: six‑month interest expense $7.4M (vs. $4.5M prior year) driven by debt amortization and high effective rates; expensive related‑party loans increase cash obligations at maturity.
- Balance‑sheet pressure: current liabilities ($120,085) far exceed current assets ($7,520) - creates immediate liquidity risk despite available restricted cash and MTEC receipts.

Bottom line / actionable takeaway
Armata is demonstrably advancing its science with encouraging clinical signals - a critical strategic positive. But the near‑term picture is dominated by a tight cash runway, heavy short‑term debt, and earnings volatility from fair‑value accounting of the convertible loan. The company's survival and ability to run pivotal trials hinge on near‑term financing (debt, equity, grants or strategic partner). Investors should weigh the clinical upside against material going‑concern and dilution/default risks tied to its financing strategy.

If you want, I can produce a one‑page spreadsheet of the key balance sheet / income numbers and runway estimate based on current cash burn.